Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRXG-K-1939 + Adebrelimab in Advanced Solid Tumors
NCT05942378Phase 1Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jul 2023
- Primary completion
- Sep 2025
- Modality
- Vaccine mRNA, mRNA Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RGL-270 in solid tumor (advanced stage), sponsored by Fudan University. Primary endpoints: Recommended Phase 2 Dose at 9 months and Antigen-Specific T-cell Responses in Peripheral Blood at 12 months. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
RGL-270
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05942378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942378.